GlassScriptPhysician profile
Donna Clay Gerhardstein
NPI 1083628978
$4,124.40
in general payments reported to CMS, 2019-2025
31 companies · $175 in 2025
The $175 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,194 · 2020: $452 · 2021: $252 · 2022: $610 · 2023: $883 · 2024: $558 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,615.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $465.96 | 2019-2024 | Ofev, Stiolto Respimat |
| Glaxosmithkline, LLC. | $414.11 | 2019-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Astrazeneca Pharmaceuticals LP | $389.07 | 2019-2024 | |
| Gilead Sciences, INC. | $252.09 | 2022-2024 | Veklury |
| Mylan Specialty L.P. | $234.78 | 2019-2024 | Yupelri |
| Genzyme Corporation | $231.65 | 2019-2024 | |
| Inari Medical, INC. | $215.89 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Actelion Pharmaceuticals US, INC. | $168.70 | 2019-2024 | Uptravi, Opsumit |
| Grifols USA, LLC | $153.51 | 2019-2023 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $148.68 | 2019-2023 | Dupixent |
| Amgen INC. | $140.61 | 2022-2025 | Tezspire |
| Pfizer INC. | $139.65 | 2019 | |
| Genentech USA, INC. | $125.77 | 2019-2023 | Xolair |
| Janssen Pharmaceuticals, INC | $115.18 | 2019-2022 | |
| Galvanize Therapeutics, INC | $113.12 | 2023 | Aliya System |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $110.13 | 2022-2025 | Tyvaso, Tyvaso |
| Teleflex LLC | $105.20 | 2025 | Arrow |
| Bayer Healthcare Pharmaceuticals INC. | $99.43 | 2019 | |
| Insmed, INC. | $80.60 | 2023-2024 | Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $79.58 | 2021-2025 | Aralast |
| Mallinckrodt Hospital Products INC. | $68.09 | 2022-2023 | Acthar |
| Sunovion Pharmaceuticals INC. | $49.65 | 2019 | |
| Merck Sharp & Dohme LLC | $44.12 | 2019 | |
| Circassia INC. | $31.62 | 2019 | |
| Tempus Ai, INC | $29.42 | 2024 | |
| Baxter Healthcare | $29.31 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Jazz Pharmaceuticals INC. | $25.23 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.57 | 2019 | |
| Shire North American Group INC | $15.80 | 2019 | |
| Astellas Pharma US INC | $14.95 | 2019 | |
| Electromed, INC. | $12.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Gerhardstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.